Last reviewed · How we verify

Empagliflozin (Jardiance®)

University Hospital Tuebingen · FDA-approved active Small molecule

Empagliflozin (Jardiance®) is a SGLT2 inhibitor Small molecule drug developed by University Hospital Tuebingen. It is currently FDA-approved for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.

Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.

Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion. Used for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.

At a glance

Generic nameEmpagliflozin (Jardiance®)
SponsorUniversity Hospital Tuebingen
Drug classSGLT2 inhibitor
TargetSGLT2 (sodium-glucose cotransporter 2)
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

SGLT2 is responsible for reabsorbing filtered glucose in the proximal tubule of the nephron. By blocking this transporter, empagliflozin allows glucose to be excreted in the urine, thereby lowering blood glucose levels independently of insulin secretion. This mechanism also promotes modest osmotic diuresis and has cardiovascular and renal protective effects beyond glycemic control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Empagliflozin (Jardiance®)

What is Empagliflozin (Jardiance®)?

Empagliflozin (Jardiance®) is a SGLT2 inhibitor drug developed by University Hospital Tuebingen, indicated for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.

How does Empagliflozin (Jardiance®) work?

Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.

What is Empagliflozin (Jardiance®) used for?

Empagliflozin (Jardiance®) is indicated for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.

Who makes Empagliflozin (Jardiance®)?

Empagliflozin (Jardiance®) is developed and marketed by University Hospital Tuebingen (see full University Hospital Tuebingen pipeline at /company/university-hospital-tuebingen).

What drug class is Empagliflozin (Jardiance®) in?

Empagliflozin (Jardiance®) belongs to the SGLT2 inhibitor class. See all SGLT2 inhibitor drugs at /class/sglt2-inhibitor.

What development phase is Empagliflozin (Jardiance®) in?

Empagliflozin (Jardiance®) is FDA-approved (marketed).

What are the side effects of Empagliflozin (Jardiance®)?

Common side effects of Empagliflozin (Jardiance®) include Genital mycotic infections, Urinary tract infections, Polyuria, Diabetic ketoacidosis, Volume depletion / hypotension.

What does Empagliflozin (Jardiance®) target?

Empagliflozin (Jardiance®) targets SGLT2 (sodium-glucose cotransporter 2) and is a SGLT2 inhibitor.

Related